BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates for KRAS inhibitor AMG 510 slip

...out of options.” For previously treated NSCLC, a docetaxel...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

...of Sanofi (Euronext:SAN; NASDAQ:SNY), announced a collaboration to advance clinical studies of KN026 plus Taxotere docetaxel...
BioCentury | May 26, 2020
Distillery Therapeutics

Disrupting mitochondrial DNA-mediated paracrine signaling for prostate cancer

...mtDNA) released from prostate cancer cells could treat prostate cancer and enhance the efficacy of docetaxel...
...antagonist tool compound or fibroblast-specific TLR9 knockout reduced tumor growth. The C3AR1 antagonist also resensitized docetaxel-resistant...
...cancer cells co-cultured with CAFs, and reduced tumor growth in a xenograft mouse model of docetaxel-resistant...
BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

...event associated with Bcl-XL inhibition. In xenograft mouse models of TNBC and SLCL, DT2216 plus docetaxel...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...checkpoint inhibitors such as Opdivo nivolumab have shown response rates of 20%; chemotherapies such as docetaxel...
BioCentury | Aug 22, 2019
Translation in Brief

Systems biology orders strategy to avoid cross-drug resistance in cancer

...predictions in mice with breast tumors rendered tolerant to anthracyclines via treatment with the taxane docetaxel...
BioCentury | Jun 1, 2019
Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

...diseases with poor prognoses. In one abstract, the FDA authors find they can switch the docetaxel...
BioCentury | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

...$71.3 million in cash and a 12-month operating loss of $65.6 million. MM-310 is a docetaxel...
BioCentury | Mar 15, 2019
Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

...and Co. (NYSE:LLY) drug is already approved in the U.S. and EU in combination with docetaxel...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...Inc. (NYSE:PFE) / Clovis Oncology Inc. (NASDAQ:CLVS) Rubraca rucaparib Ph III Monotherapy Zytiga, Xtandi or docetaxel...
...testing Merck & Co.’s Keytruda pembrolizumab in combination with Xtandi, PARP inhibitor Lynparza olaparib, or docetaxel...
...were underwhelming. ORRs were 20% in combination with Xtandi, 7% with Lynparza and 14% with docetaxel...
Items per page:
1 - 10 of 1566